• news.cision.com/
  • AstraZeneca/
  • AstraZeneca reaffirms December 2011 financial guidance for 2011 and mid-term planning assumptions for the 2010 to 2014 period
Svenska

AstraZeneca reaffirms December 2011 financial guidance for 2011 and mid-term planning assumptions for the 2010 to 2014 period

Report this content

 

During a routine consensus collection process, confidential Company information was inadvertently embedded in a spreadsheet template sent to the sell-side analyst community that follows the Company.  This information is out of date planning information, and does not represent the Company’s view of expected financial performance for the full year 2011 or for future periods. 

The most recent update of the Company’s financial guidance for 2011 was issued on 20 December 2011.  Today, the Company reaffirms this guidance; the Company continues to expect to report Core earnings per share for the Full Year 2011 in the lower half of the range of $7.20 to $7.40.

In addition, the Company today reaffirms its planning assumptions for revenue, margins and cash deployment for the period 2010 to 2014, which were most recently updated in January 2011.

In line with its usual practice, the Company will provide specific financial guidance for 2012 and any updates to 2010 to 2014 mid-term planning assumptions, in conjunction with its Full Year 2011 financial results announcement, scheduled for 2 February 2012. 

– ENDS –

NOTES TO EDITORS

About AstraZeneca
AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialisation of prescription medicines for gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com

CONTACTS

Media Enquiries

Esra Erkal-Paler                          +44 20 7604 8030 (24 hours)
Abigail Baron                              +44 20 7604 8034 (24 hours)
Isabelle Jouin                              +44 20 7604 8031 (24 hours)

Investor Enquiries UK

James Ward-Lilley                      +44 20 7604 8122
Karl Hård                                   +44 20 7604 8123 mob: +44 7789 654364
Nicklas Westerholm                    +44 20 7604 8124 mob: +44 7585 404950

Investor Enquiries US

Ed Seage                                    +1 302 886 4065   mob: +1 302 373 1361
Jörgen Winroth                           +1 212 579 0506   mob: +1 917 612 4043

 

 

Taggar:

AstraZeneca guidance

Prenumerera